Translational control of gene expression and disease

Trends in Molecular Medicine

Volumn 8, Issue 12, 2002, Pages 577-583

  Calkhoven, Cornelis F ^a   Müller, Christine ^a   Leutz, Achim ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; MESSENGER RNA;

CANCER; CATARACT; CELL CYCLE; CELL DIFFERENTIATION; CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; GENE EXPRESSION REGULATION; GENE MUTATION; HYPERFERRITINEMIA; LEUKOENCEPHALOPATHY; MENTAL RETARDATION MALFORMATION SYNDROME; REGULATORY MECHANISM; REVIEW; RNA TRANSLATION; SYNDROME; THROMBOCYTHEMIA; WOLCOTT RALLISON SYNDROME;

EID: 0036892346     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(02)02424-3     Document Type: Review

References (61)

1. Sonenberg, N. et al. eds (2000) Translational Control of Gene Expression, Cold Spring Harbor Laboratory Press, New York, NY, USA
2. Dever, T.E. (2002) Gene-specific regulation by general translation factors. Cell 108, 545-556
3. Gingras, A.C. et al. (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852-2864
4. Harding, H.P. et al. (2000) Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol. Cell 5, 897-904
5. Delepine, M. et al. (2000) EIF2AK3, encoding translation initiation factor 2-α kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. 25, 406-409
6. -/- mice reveals a role for translational control in secretory cell survival. Mol. Cell 7, 1153-1163
7. Zhang, P. et al. (2002) The PERK eukaryotic initiation factor 2-α kinase is required for the development of the skeletal system, postnatal growth, and the function and viability of the pancreas. Mol. Cell. Biol. 22, 3864-3874
8. Scheuner, D. et al. (2001) Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol. Cell 7, 1165-1176
9. Leegwater, P.A. et al. (2001) Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. Nat. Genet. 29, 383-388
10. Verkerk, A.J. et al. (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905-914
11. De Boulle, K. et al. (1993) A point mutation in the FMR- 1 gene associated with fragile X mental retardation. Nat. Genet. 3, 31-35
12. Oostra, B.A. (2002) Functions of the fragile X protein. Trends Mol. Med. 8, 102-103
13. Brown, V. et al. (2001) Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107, 477-487
14. Darnell, J.C. et al. (2001) Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 107, 489-499
15. Perrotti, D. et al. (2002) BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2. Nat. Genet. 30, 48-58
16. Porse, B.T. et al. (2001) E2F repression by C/EBPα is required for adipogenesis and granulopoiesis in vivo. Cell 107, 247-258
17. Gombart, A.F. et al. (2002) Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein a in myelodysplastic syndromes and acute myeloid leukemias. Blood 99, 1332-1340
18. Cazzola, M. and Skoda, R.C. (2000) Translational pathophysiology: A novel molecular mechanism of human disease. Blood 95, 3280-3288
19. Beaumont, C. et al. (1995) Mutation in the iron responsive element of the L-ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nat. Genet. 11, 444-446
20. Testa. J.R. and Bellacosa, A. (2001) AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 98, 10983-10985
21. Shayesteh, L. et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet. 21, 99-102
22. Marte, B.M. and Downward, J. (1997) PKB/Akt: Connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem. Sci. 22, 355-358
23. Gingras, A.C. et al. (1998) 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12, 502-513
24. Gingras, A.C. et al. (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15, 807-826
25. Dennis, P.B. et al. (2001) Mammalian TOR: A homeostatic ATP sensor. Science 294, 1102-1105
26. Schmelzle, T. and Hall, M.N. (2000) TOR, a central controller of cell growth. Cell 103, 253-262
27. s6k. EMBO J. 16, 3693-3704
28. Aoki, M. et al. (2001) A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc. Natl. Acad. Sci. U. S. A. 98, 136-141
29. Simpson, L. and Parsons, R. (2001) PTEN: Life as a tumor suppressor. Exp. Cell Res. 264, 29-41
30. Groszer, M. et al. (2001) Negative regulation of neural stem/progenitor cell proliferation by the PTEN tumor suppressor gene in vivo. Science 294, 2186-2189
31. Lazaris-Karatzas, A. et al. (1990) Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345, 544-547
32. Lazaris-Karatzas, A. and Sonenberg, N. (1992) The mRNA 5′ cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts. Mol. Cell. Biol. 12, 1234-1238
33. Dua, K. et al. (2001) Translational control of the proteome: Relevance to cancer. Proteomics 1, 1191-1199
34. Rosenwald, I.B. et al. (1999) Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 18, 2507-2517
35. Anthony. B. et al. (1996) Overexpression of the proto-oncogene/translation factor 4E in breast-carcinoma cell lines. Int. J. Cancer 65, 858-863
36. DeFatta, R.J. et al. (1999) Elevated expression of eIF4E in confined early breast cancer lesions: Possible role of hypoxia. Int. J. Cancer 80, 516-522
37. Wang, S. et al. (1999) Expression of the eukaryotic translation initiation factors 4E and 2α in non-Hodgkin's lymphomas. Am. J. Pathol. 155, 247-255
38. Crew, J.P. et al. (2000) Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br. J. Cancer 82, 161-166
39. Rosenwald, I.B. et al. (1993) Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2α in response to growth induction by c-myc. Proc. Natl. Acad. Sci. U. S. A. 90, 6175-6178
40. Donze, O. et al. (1995) Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells. EMBO J. 14, 3828-3834
41. Rosenwald, I.B. (1996) Upregulated expression of the genes encoding translation initiation factors eIF-4E and eIF-2α in transformed cells. Cancer Lett. 102, 113-123
42. Palakurthi, S.S. et al. (2000) Inhibition of translation initiation mediates the anticancer effect of the n-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer Res. 60, 2919-2925
43. Palakurthi, S.S. et al. (2001) Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res. 61, 6213-6218
44. 2+ stores, phosphorylation of eIF2α, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc. Natl. Acad. Sci. U. S. A. 95, 8280-8285
45. Kozak, M. (1991) An analysis of vertebrate mRNA sequences: Intimations of translational control. J. Cell Biol. 115, 887-903
46. kip1 accumulation during the cell cycle. Science 271, 1861-1864
47. Rousseau, D. et al. (1996) Translation initiation of ornithine decarboxilase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc. Natl. Acad. Sci. U. S. A. 93, 1065-1070
48. Ghilardi, N. et al. (1998) Thrombopoietin production is inhibited by a translational mechanism. Blood 92, 4023-4030
49. Harigai, M. et al. (1996) A cis-acting element in the BCL-2 gene controls expression through translational mechanisms. Oncogene 12, 1369-1374
50. Calkhoven, C.F. et al. (2000) Translational control of C/EBPα and C/EBPβ isoform expression. Genes Dev. 14, 1920-1932
51. Harding, H.P. et al. (2000) Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol. Cell 6, 1099-1108
52. Descombes, P. and Schibler, U. (1991)A liven-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 67, 569-579
53. Ossipow, V. et al. (1993) CCAAT/enhancer-binding protein mRNA is translated into multiple proteins with different transcription activation potentials. Proc. Natl. Acad. Sci. U. S. A. 90, 8219-8223
54. Lin, F.T. et al. (1993) A 30-kDa alternative translation product of the CCAAT/enhancer binding protein a message: Transcriptional activator lacking antimitotic activity. Proc. Natl. Acad. Sci. U. S. A. 90, 9606-9610
55. Kowenz-Leutz, E. and Leutz, A. (1999) A C/EBPβ isoform recruits the SWI/SNF complex to activate myeloid genes. Mol. Cell 4, 735-743
56. Raught, B. et al. (1996) Expression of a translationally regulated, dominant-negative CCAAT/enhancer-binding protein β isoform and up-regulation of the eukaryotic translation initiation factor 2α are correlated with neoplastic transformation of mammary epithelial cells. Cancer Res. 56, 4382-4386
57. Rask, K. et al. (2000) Increased expression of the transcription factors CCAAT-enhancer binding protein-β (C/EBPβ) and C/EBPζ (CHOP) correlate with invasiveness of human colorectal cancer. Int. J. Cancer 86, 337-343
58. Hidalgo, M. and Rowinsky,. E.K. (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680-6686
59. Neshat, M.S. et al. (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. U. S. A. 98, 10314-10319
60. Louro, I.D. et al. (1999) The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin. Cell Growth Differ. 10, 503-516
61. Guba, M. et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat. Med. 8, 128-135